mGluR2 x mGluR3

New class of drugs focuses on alcohol use disorder SAN DIEGO, Dec. 7, 2023 /PRNewswire/ -- Camino Pharma, LLC, a biotech company focused on finding cures for cancer and brain disorders, announced today that its co-founder and CSO, Reto Gadient, Ph.D., has been awarded a two-year, $1.97M grant by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health under Award Number U43AA031388 and is the Principal Investigator (PI) on the grant. The grant will fund a collaborative effort between Camino Pharma, LLC, Sanford Burnham Prebys and Wake Forest University School of Medicine to validate positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGlu2) for the treatment of alcohol use disorder (AUD). "This exciting collaboration between Camino Pharma, Sanford Burnham Prebys and Wake Forest University School of Medicine will facilitate the development of novel therapeutic options for patients afflicted with AUD," says Gonul Velicelebi, Ph.D., co-founder and CEO of the company. "We are optimistic that our mGlu2 PAMs, all discovered at Sanford Burnham Prebys, could provide us with a positive preclinical proof-of-concept in relevant rodent models of AUD. Such a result would support advancing one of our mGlu2 PAMs towards clinical development to target AUD," adds Gadient. The grant will enable the multidisciplinary team of scientists to evaluate mGlu2 PAMs in two rodent models of alcohol dependence. "These models show symptoms and behaviors seen in patients with AUD, such as increased alcohol consumption, binge drinking, withdrawal and sleep disturbances. Reducing alcohol intake, withdrawal symptoms or improving sleep in these models will provide us with compelling evidence that efficacy may be obtained in the clinic," says Robert Warren Gould, Ph.D., Assistant Professor at Wake Forest University School of Medicine and a co-PI on the grant. "A large body of experimental evidence suggests that elevated glutamate neurotransmission is involved in the pathophysiology of substance use disorders, including AUD," says Douglas Sheffler, Ph.D., Research Assistant Professor at Sanford Burnham Prebys, also a co-PI on the grant. "Our compounds decrease glutamate neurotransmission by positively modulating mGlu2, and therefore represent a novel mechanism distinct from other drugs currently in use for the treatment of AUD." About metabotropic glutamate receptors (mGlus) The mGlu receptors are a family of eight subtypes of G protein-coupled glutamate receptors that are widely expressed in the central nervous system (CNS) and are classified into three groups based on sequence homology and signaling mechanisms. The group II mGlus (mGlu2 and mGlu3) are located presynaptically at glutamatergic synapses where they play a key role in maintaining glutamate homeostasis. mGlu2 and mGlu3 are abundantly expressed in forebrain regions affected in depression, where they modulate glutamate transmission and the release of other neurotransmitters involved in reward processing. mGlu2 and mGlu3 are also abundantly expressed in brain regions implicated in drug abuse and addiction, including the cortex, hippocampus, striatum and amygdala. Thus, negative modulators of presynaptic mGlu2 and mGlu3 represent a new class of drugs to treat depression, and positive modulators for substance use disorders, including AUD. Camino Pharma is collaborating with Sanford Burnham Prebys to pursue both strategies. About Camino Pharma, LLC () Camino Pharma is a San Diego–based start-up focused on discovering and developing first-in-class therapies for patients afflicted with cancer and CNS disorders. We target signaling proteins based on emerging biological concepts and discover novel mechanisms for modulating these targets with small molecule drugs. Our leadership team has proven expertise in the relevant target biology, as well as extensive experience in drug discovery and development. Our goal is to discover and develop novel, first-in-class to treat (1) the most aggressive forms of cancer with currently limited treatment options, and (2) psychiatric disorders that are poorly addressed by current medications, including substance use and major depression. Our innovative technology platform allows for exploiting inadequately served targets that require a highly adaptive and specialized approach to drug discovery. We intend to use our deep understanding in target biology, combined with extremely tailored, cutting-edge discovery technologies, to find novel cures. SOURCE Camino Pharma, LLC

Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023. Tim Dyer, CEO, Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics to Announce Half-Year 2023 Financial Results and Provides Corporate Update Date: August 10, 2023Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) Joining the Conference Call: Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number. Online Registration: https://register.vevent.com/register/BI3df82968423c4258930719a84f76d6bf Webcast URL: https://edge.media-server.com/mmc/p/gp4h8rth About Addex Therapeutics:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional, non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2 clinical trial for the treatment of epilepsy. Addex's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder. Addex is also advancing a broad preclinical pipeline, which includes development of a range of GABAB PAMs for CMT1A, chronic cough and several types of pain, mGlu7 NAM for stress related disorders, mGlu2 NAM for mild neurocognitive disorders and depression, M4 PAM for schizophrenia and other forms of psychosis, as well as mGlu4 PAM and mGlu3 PAM. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@addextherapeutics.comMike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@halsin.com Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2022, as filed with the SEC on March 30, 2023, the final prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Discovery collaboration on track to deliver clinical candidates for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: INDV) for the discovery of novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates for the treatment of substance use disorder has been extended until June 30, 2024. As part of the extended agreement, Indivior has committed CHF 2.7 million to support research and discovery activities during this period. Addex retains exclusive rights to advance its own independent GABAB PAM program and is developing compounds for the treatment of chronic cough. “We are excited to continue working closely with Indivior in this promising application of our allosteric modulator discovery platform,” said Tim Dyer, CEO of Addex. “Indivior’s commitment to the substance use disorder program demonstrates the solid progress being made in the advancement of promising GABAB PAM candidates with the optimal characteristics needed for success in the clinic.” About GABAB Activation with PAM:Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically and commercially validated. The generic GABAB receptor agonist, baclofen, marketed for spasticity and some spinal cord injuries, has been shown to be efficacious in several other disease areas, including alcohol use disorder, CMT1A, chronic cough and pain. However, its wider use is limited due to a variety of side effects, rapid clearance and the development of tolerance. Novel, potent, selective and orally available positive allosteric modulators (PAMs) that potentiate GABA responses, rather than acting as orthosteric agonists at the GABAB receptor, like baclofen, are expected to deliver efficacy and have fewer adverse effects. Furthermore, PAMs only act when the natural ligand (GABA) activates the receptor, hence respecting the physiological cycle of activation, which may explain why PAMs lead to less tolerance than direct agonists. About Addex Therapeutics:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional, non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2 clinical trial for the treatment of epilepsy. Addex's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in post-stroke recovery. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder. Addex is also advancing a broad preclinical pipeline, which includes development of GABAB PAM for chronic cough, M4 PAM for schizophrenia and other forms of psychosis, mGlu7 NAM for stress related disorders, mGlu2 NAM for mild neurocognitive disorders and depression, as well as mGlu4 PAM and mGlu3 PAM. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange. Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55 PR@addextherapeutics.com Mike SinclairPartner, Halsin Partners+44 (0)20 7318 2955msinclair@halsin.com Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2022, as filed with the SEC on March 30, 2023, the final prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.